Please assess the completion status of the following clinical trial:

Trial Title: Velcade in Myelodysplastic Syndrome - Pilot Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 -75 years.~* Patients with the following clinical diagnosis: RA(FAB) or RCMD (WHO), RARS (FAB) or RCDM-RS(WHO), RAEB (FAB) or RAEB I (WHO), RAEB II (WHO), and:~  * IPSS intermediate-2 (score 1.5-2) or high (score 2.5-3) not previously treated with chemotherapy (CT) and not eligible for intensive chemotherapy or allogeneic stem cell transplantation (SCT), or~ * IPSS intermediate-1(score 0.5-1) or low (score 0), EPO or immunosuppressive (Cyclosporine, CSA; anti-tymocyte globulin, ATG) therapies resistant or not eligible for these therapies, and transfusion dependent.~* Patients willing and able to comply with the protocol requirements.~* Patients given voluntary written informed consent to participate in the study, with the understanding that consent may be withdrawn at any time without prejudice to future medical care.~* Male and female patients willing to use acceptable methods for contraception, for the duration of the study.~* Patients with WHO performance Status (PS) 0-2, and life expectancy \> 3 months.~* Renal function tests ≤ 2 x upper limit of normal values.~* AST/GOT, ALT/GPT ≤ 2.5 x upper limit of normal values.~* Total bilirubine ≤ 1.5 x upper limit of normal value.~Exclusion Criteria:~* Patient has Grade 2 (as defined by the NCI Common Toxicity Criteria-CTC) peripheral neuropathy within 14 days before enrollment.~* Patient has hypersensitivity to bortezomib, boron or mannitol.~* Patient has received prior treatment with bortezomib~* Patient is pregnant or nursing~* Patient has received other investigational drugs within 14 days before enrollment~* Patient has received prior chemotherapy~* Patient had a major surgery within 4 weeks before enrollment~* Patient had myocardial infarction within 6 months of enrollment or has class III-IV heart failure, uncontrolled angina or arrhythmias~* Patient has been treated for previous malignancy within 5 years before enrollment~* Patient has uncontrolled hypertension or diabetes mellitus~* Patient is known to have HBV or HCV active hepatitis or is human immunodeficiency virus (HIV)-positive~* Patient has systemic infections requiring treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).